Elliott builds stake in Bio-Rad to boost stock price
Activist investor Elliott Investment Management has acquired a stake in Bio-Rad Laboratories. The firm plans to push for improved share price performance.
Elliott Investment Management built a stake in Bio-Rad Laboratories to push for a higher stock price, according to the Wall Street Journal. Shares of the diagnostics supplier have fallen 18% since the start of the year. Elliott also took a position in Sartorius-based biopharma equipment maker to capitalize on growth potential.
### Elliott Targets Value in Sartorius Holding The activist investor plans to pressure Bio-Rad to address its underperforming valuation, according to people familiar with the matter. Bio-Rad shares closed at $246.53 the prior week, resulting in a $6.69 billion market capitalization. Elliott believes Sartorius is a strong business with growth potential despite recent volatility in the healthcare sector.
